Why One-Time Cannabis Darling Tilray Is Now High On Beer

Tilray: From Cannabis Darling to Beer Baron

Key Concepts:

Cannabis industry challenges (legalization delays, competition)
Diversification strategy (alcohol, pharmaceuticals)
Reverse stock split
Revenue streams (cannabis, alcohol, pharmaceuticals, wellness)
Cannibalization of alcohol sales by cannabis

Tilray's Rise and Fall in the Cannabis Market

In July 2018, Tilray, a Canadian cannabis company, went public on the NASDAQ, marking a significant moment as one of the first cannabis firms to list on a major US exchange. The stock surged 35% on its first day, reaching a peak of $214 per share and a valuation of $17 billion, despite only having $27.7 million in revenue. However, the stock has since experienced a significant decline, falling below $1 due to:

Lack of Federal Legalization in the US: Seven years of stagnation in US federal marijuana legalization efforts.
Intense Competition in Canada: A highly competitive and relatively small Canadian cannabis market.

The NASDAQ issued a delisting warning to Tilray due to its low stock price.

Irwin Simon's Turnaround Plan: Diversification Beyond Cannabis

Irwin Simon, who became CEO of Tilray in 2021 after the merger with Aphria (where he was previously CEO), is implementing a diversification strategy to revive the company. He plans to execute a reverse stock split to bring the share price above $1 and avoid delisting. Simon, who previously built Haynes Celestial Group into a $3 billion organic food business, believes Tilray needs to be more than just a cannabis company.

Acquisition of Craft Beer and Spirits Brands

A key element of Simon's strategy is the acquisition of craft beer and spirits brands. Tilray has acquired:

Eight craft beer companies from Anheuser-Busch.
Four craft beer companies from Molson Coors.

This makes Tilray the fourth-largest craft brewer in the US, with brands like:

Montauk Brewing (New York)
Sweetwater (Georgia)
Breckenridge Brewery (Colorado)

Tilray also owns Breckenridge Distillery, a Colorado-based blended bourbon whiskey maker.

Financial Performance and Revenue Streams

Despite generating $788 million in overall revenue last year, Tilray reported a net loss of $222 million, primarily due to non-cash expenses. However, the company has $230 million in cash and has reduced its losses from $1.4 billion in 2023. Tilray's revenue streams are now diversified:

Cannabis: $275 million in total cannabis sales annually ($80 million from medical marijuana). Cannabis accounts for 35% of revenue.
Alcohol: 25% of revenue.
Pharmaceutical Distribution: 33% of revenue, primarily in Europe, distributing medical cannabis and other medications.
Wellness: 7% of revenue, including hemp-based food brands like Manitoba Harvest.

Tilray's Perspective and Market Positioning

Simon emphasizes that Tilray is not just a "weed" company but a diversified pharmaceutical and consumer packaged goods company focused on "bringing people together for a good time." He aims to shift investor perception of the brand.

Cannibalization of Alcohol Sales

Ironically, the growth of legal cannabis is impacting the beer industry. According to the Brewers Association, craft beer production decreased by 4% in 2024, marking the third consecutive year of decline. Simon acknowledges this trend, stating, "Cannabis does ultimately cannibalize alcohol sales. If I get cannibalized on one end, I want to be in the business that's cannibalizing."

Conclusion

Tilray, once a cannabis darling, is now heavily invested in the alcohol industry as part of a diversification strategy to combat challenges in the cannabis market. CEO Irwin Simon is betting on this diversification, along with a pharmaceutical distribution arm, to transform Tilray into a broader consumer packaged goods company and revive its stock price. The company faces the challenge of navigating the cannibalization of alcohol sales by cannabis while positioning itself as a diversified player in the "good times" market.